EMY covers FDA approval of Zepbound for obstructive sleep apnea
Lilly's tirzepatide shot Zepbound is cleared by the FDA to treat obstructive sleep apnea, adding a use beyond weight loss.
Recap by typeshit. Full story at emy.
Read at emy
More peptides
-
Novo's weekly IcoSema shot pairing insulin icodec and semaglutide moves ahead in Europe 
Novo's weekly IcoSema shot pairing insulin icodec and semaglutide moves ahead in Europe
The EMA's CHMP amended its type 2 diabetes indication, and Italian diabetologists say Italy could be the first European country to offer the once-weekly combo.
-
TakingWeightOff shares what three weeks off tirzepatide has been like 
26:19
TakingWeightOff shares what three weeks off tirzepatide has been like
A personal update from TakingWeightOff on life after stopping tirzepatide, three weeks in, and what caught them off guard.
-
Eli Lilly opens a new fight over a weight loss drug still awaiting FDA approval Eli Lilly opens a new fight over a weight loss drug still awaiting FDA approval
Nyah Phengsitthy reports Lilly is staking out a new battlefront around an unapproved obesity treatment. The full story has the details.
-
MM+M traces medical marketing from patent medicine shows to semaglutide 
MM+M traces medical marketing from patent medicine shows to semaglutide
A history of drug advertising, from opium-laced tonics and Radithor to the 1938 law after Elixir Sulfanilamide killed over 100 people. Semaglutide is mostly a hook.
-
Benjamin Bikman explains how retatrutide's glucagon action targets the liver 
peptides typeshitResearchBenjamin Bikman explains how retatrutide's glucagon action targets the liver
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
-
Jamie Geller talks with Dr. Yardena Bauer about GLP-1s and cravings 
Jamie Geller talks with Dr. Yardena Bauer about GLP-1s and cravings
Bauer argues weight loss was never about willpower and describes how GLP-1 drugs can quiet cravings. Full episode on the podcast.
